Polyendocrine Metabolic Ovarian Syndrome: A Brief Review.

Background

Polyendocrine metabolic ovarian syndrome (PMOS) is a prevalent endocrine disorder affecting 10-13% of reproductive-aged women. Characterized by hyperandrogenism, ovulatory dysfunction, and metabolic disturbances, its management is increasingly focused on the gut-brain-ovary axis and chronic low-grade inflammation. This review examines current evidence for lifestyle-based, nutritional, and pharmacologic interventions in PMOS management.

Methods

A review of current literature and clinical guidelines was conducted, focusing on pathophysiology, including genetic, hormonal, and inflammatory drivers, and therapeutic strategies.

Results

Lifestyle modification remains the primary therapy, improving insulin sensitivity, menstrual regularity, and psychological well-being. Pharmacologic adjuncts like metformin and oral contraceptives address specific metabolic and reproductive symptoms. Nutritional supplementation, particularly a 40:1 ratio of myo-inositol to D-chiro-inositol, shows significant efficacy in restoring ovarian function. Emerging research highlights the role of gut dysbiosis in driving systemic inflammation and hormonal dysregulation.

Conclusion

Effective PMOS management requires an individualized, multimodal approach that integrates lifestyle medicine with targeted supplementation and pharmacotherapy to address the complex metabolic and reproductive features of the syndrome.